Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2007

View Archived Issues

Investigational prokinetic 5-HT4 agonist advancing through the pipeline

Support for activation of SIRT1 as a novel approach to type 2 diabetes

Cadence increases enrollment of phase III trial of Omigard for LCSI reduction

Quigley Pharma initiates clinical trial of QR-449 for metabolic syndrome

Positive results for Phytopharm's liquid formulation of Myogane

Elan announces second quarter 2007 results

Positive results for Biolex's phase IIa trial of Locteron for hepatitis C

Ranbaxy claims new drugs for respiratory disorders

New treatment options for dermatological disorders divulged in recent patent

Recent patent literature discloses new antiobesity drugs

EvaMist approved by the FDA

Symposium features Sirtex's SIR-Spheres for colorectal liver metastases

Anadys and Novartis discontinue development of ANA-975 for HCV

Abbott voluntarily withdraws E.U. marketing authorization for Trudexa

Targacept initiates phase I clinical trial of TC-5619

ReNeuron acquires business assets from AmCyte

Threshold begins phase I trial of TH-302 for solid tumors

Regulatory update on satraplatin

GSK and Targacept to codevelop novel NNRs targeting therapeutics

Toyama receives marketing approval for Geninax in Japan

Clinical evaluation to commence for a new agent for hyperlipidemia

Eisai to begin trial to determine MTD of E-7107 in cancer patients

Elixir presents data on ghrelin- and sirtuin-based programs for metabolic diseases

Fludarabine plus cyclophosphamide for the treatment of CLL

First small-molecule HIV-1 Tat-PP-1 inhibitors designed to inhibit HIV-1 transcription described

Comparison of different formulations of mycophenolic acid in IgA nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...